MA49545A1 - Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci - Google Patents

Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Info

Publication number
MA49545A1
MA49545A1 MA49545A MA49545A MA49545A1 MA 49545 A1 MA49545 A1 MA 49545A1 MA 49545 A MA49545 A MA 49545A MA 49545 A MA49545 A MA 49545A MA 49545 A1 MA49545 A1 MA 49545A1
Authority
MA
Morocco
Prior art keywords
long
composition
glucagon derivative
acting conjugate
glucagon
Prior art date
Application number
MA49545A
Other languages
English (en)
Other versions
MA49545B1 (fr
Inventor
Sung Youb Jung
In Young Choi
Jung Kuk Kim
Young Jin Park
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA49545A1 publication Critical patent/MA49545A1/fr
Publication of MA49545B1 publication Critical patent/MA49545B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un dérivé de glucagon, un conjugué de glucagon à action prolongée du dérivé de glucagon, une utilisation de ceux-ci.
MA49545A 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci MA49545B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150093265 2015-06-30
PCT/KR2016/006984 WO2017003191A1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Publications (2)

Publication Number Publication Date
MA49545A1 true MA49545A1 (fr) 2021-09-30
MA49545B1 MA49545B1 (fr) 2022-03-31

Family

ID=57608802

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41887A MA41887B1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
MA49545A MA49545B1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41887A MA41887B1 (fr) 2015-06-30 2016-06-29 Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci

Country Status (31)

Country Link
US (3) US10696725B2 (fr)
EP (3) EP3322437B1 (fr)
JP (3) JP6882210B2 (fr)
KR (2) KR102005456B1 (fr)
CN (1) CN108025041A (fr)
AR (1) AR105485A1 (fr)
AU (2) AU2016287209B2 (fr)
CA (2) CA3273336A1 (fr)
CL (5) CL2017003402A1 (fr)
CO (1) CO2018000303A2 (fr)
CR (1) CR20180034A (fr)
DK (1) DK3322437T5 (fr)
DO (1) DOP2017000318A (fr)
EA (1) EA201890058A1 (fr)
EC (1) ECSP18003879A (fr)
ES (1) ES2973017T3 (fr)
FI (1) FI3322437T3 (fr)
HU (1) HUE066226T2 (fr)
IL (2) IL256619B (fr)
MA (2) MA41887B1 (fr)
MX (1) MX2017016845A (fr)
PE (2) PE20180449A1 (fr)
PH (1) PH12017502393A1 (fr)
PL (1) PL3322437T3 (fr)
PT (1) PT3322437T (fr)
PY (1) PY1640586A (fr)
TN (1) TN2017000555A1 (fr)
TW (1) TWI713541B (fr)
UA (1) UA127445C2 (fr)
UY (1) UY36759A (fr)
WO (1) WO2017003191A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
KR102291020B1 (ko) * 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
FI3322437T3 (fi) 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
CN122440793A (zh) * 2016-06-29 2026-07-24 韩美药品株式会社 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途
EP3578204A4 (fr) * 2017-02-03 2021-01-06 Hanmi Pharm. Co., Ltd. Conjugué de substance bioactive ayant une durabilité améliorée et son utilisation
US11925691B2 (en) 2017-02-07 2024-03-12 Hanmi Pharm. Co., Ltd. Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate
WO2019066603A1 (fr) * 2017-09-29 2019-04-04 한미약품 주식회사 Conjugué de protéine persistant à efficacité améliorée
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
KR101990075B1 (ko) * 2018-07-19 2019-06-18 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비만 예방 또는 치료용 약학 조성물
BR112021000933A2 (pt) * 2018-07-19 2021-04-27 D&D Pharmatech Inc. polipeptídeo, composição farmacêutica, método de preparação dela e método de prevenção ou tratamento de doenças
WO2020017919A1 (fr) * 2018-07-19 2020-01-23 한미정밀화학주식회사 Nouvel intermédiaire utilisé pour un polypeptide physiologiquement actif et son procédé de préparation
WO2020071865A1 (fr) * 2018-10-04 2020-04-09 한미약품 주식회사 Utilisations thérapeutiques du glucagon et produit combiné comprenant celui-ci
CN109239346B (zh) * 2018-10-31 2019-10-11 中国药科大学 一组代谢标志物在代谢综合征早期诊断方面的应用
WO2020130751A1 (fr) 2018-12-21 2020-06-25 한미약품 주식회사 Composition pharmaceutique contenant de l'insuline et du glucagon
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
MX2021015927A (es) * 2019-06-28 2022-04-18 Hanmi Pharm Ind Co Ltd Uso terapéutico de agonista trigonal de los receptores de glucagón, glp-1 y gip, o conjugado de los mismos para enfermedades hepáticas.
JP7761557B2 (ja) * 2019-10-04 2025-10-28 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CA3168001A1 (fr) * 2020-02-21 2021-08-26 Spitfire Pharma Llc Agonistes de glp-1r et gcgr, formulations et procedes d'utilisation
CA3179603A1 (fr) * 2020-05-22 2021-11-25 Hanmi Pharm. Co., Ltd. Formulation liquide d'un conjugue a action prolongee d'un derive du glucagon
BR112023000515A2 (pt) * 2020-07-15 2023-03-21 Hanmi Pharm Ind Co Ltd Composição farmacêutica e seu uso
WO2022035302A1 (fr) * 2020-08-14 2022-02-17 한미약품 주식회사 Composition pharmaceutique à effet hypotenseur comprenant un activateur triple présentant une activité pour tous les récepteurs du glucagon, de la glp-1, et de la gip
KR20220050820A (ko) * 2020-10-16 2022-04-25 한미약품 주식회사 Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
US20240197834A1 (en) 2021-04-09 2024-06-20 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (fr) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP1411968B1 (fr) 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1, exendine-4, analogues peptidiques et utilisations associees
US7557183B2 (en) 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
BRPI0406605B8 (pt) * 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
EP2471810A1 (fr) * 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Dérivés d'oxyntomoduline
EP2007804B1 (fr) 2006-04-20 2014-06-18 Amgen, Inc Composés de glp-1
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (fr) 2007-06-15 2008-12-18 Zealand Pharma A/S Analogues du glucagon
BRPI0813139A8 (pt) 2007-06-19 2019-01-29 Glytech Inc peptídeo glp-1 com adição de cadeia oligossacarídea
EP2190872B1 (fr) 2007-09-05 2018-03-14 Novo Nordisk A/S Dérivés de glucagon-like peptide-1 et leur utilisation pharmaceutique
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
TWI541023B (zh) * 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
CA2728284C (fr) 2008-06-17 2019-09-10 Richard D. Dimarchi Co-agonistes du recepteur glucagon/glp-1
WO2010096052A1 (fr) * 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Analogues d'oxyntomoduline
WO2010148089A1 (fr) * 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Composés de glucagon actifs sur le récepteur gip
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (fr) * 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
WO2011088837A1 (fr) 2010-01-20 2011-07-28 Zealand Pharma A/S Traitement d'états pathologiques cardiaques
KR20130018410A (ko) * 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
RU2012153753A (ru) 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
WO2012150503A2 (fr) 2011-05-03 2012-11-08 Zealand Pharma A/S Composés sélectifs de la signalisation d'agoniste mixte glu-glp-1
CA3134906A1 (fr) 2011-05-18 2012-11-22 Mederis Diabetes, Llc Substances pharmaceutiques peptidiques ameliorees pour la resistance a l'insuline
HRP20181591T1 (hr) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina i farmaceutski pripravci za liječenje pretilosti koji ih sadrže
TWI601744B (zh) 2011-06-17 2017-10-11 韓美科學股份有限公司 包含調酸素與免疫球蛋白片段之複合物及其用途
WO2013004983A1 (fr) 2011-07-04 2013-01-10 Imperial Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
EP2817025A2 (fr) 2012-02-08 2014-12-31 Seneb Biosciences, Inc. Traitement de l'hypoglycémie
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
EP2851429B1 (fr) 2012-05-18 2019-07-24 Adda Biotech Inc. Protéine et conjugué protéique pour le traitement du diabète et applications associées
SI2864350T1 (en) 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
EA039082B1 (ru) * 2012-11-06 2021-12-01 Ханми Фарм. Ко., Лтд. Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
EP2922877B1 (fr) 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Agents pharmaceutiques peptidiques améliorés
WO2014081872A1 (fr) 2012-11-20 2014-05-30 Mederis Diabetes, Llc Produits pharmaceutiques peptidiques améliorés pour la résistance à l'insuline
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
WO2015022420A1 (fr) 2013-08-16 2015-02-19 Medimmune Limited Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
CN107106680A (zh) * 2014-11-13 2017-08-29 江苏奥赛康药业股份有限公司 具备双受体激动剂活性的融合蛋白
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
KR102291020B1 (ko) * 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
FI3322437T3 (fi) 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
US20170004368A1 (en) 2015-07-05 2017-01-05 Neteera Technologies Ltd. System and method for biometric detection based on sweat ducts
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
US20180360973A1 (en) 2015-12-02 2018-12-20 Hanmi Pharm. Co., Ltd. Protein conjugate using a fatty acid derivative and method for preparation thereof
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体

Also Published As

Publication number Publication date
UA127445C2 (uk) 2023-08-30
US20180186853A1 (en) 2018-07-05
CL2023001910A1 (es) 2023-11-17
CL2023001909A1 (es) 2023-11-17
MX2017016845A (es) 2018-08-01
PE20180449A1 (es) 2018-03-05
US20220127325A1 (en) 2022-04-28
IL291291B2 (en) 2023-06-01
PY1640586A (es) 2018-03-01
TW201713681A (zh) 2017-04-16
DK3322437T3 (da) 2024-03-25
HUE066226T2 (hu) 2024-07-28
DK3322437T5 (da) 2024-10-07
UY36759A (es) 2017-01-31
ECSP18003879A (es) 2018-03-31
CN108025041A (zh) 2018-05-11
PL3322437T3 (pl) 2024-05-20
DOP2017000318A (es) 2018-04-30
TWI713541B (zh) 2020-12-21
IL256619B (en) 2022-04-01
AU2016287209B2 (en) 2023-03-02
MA41887A1 (fr) 2018-12-31
IL256619A (en) 2018-04-30
EP3322437A4 (fr) 2019-10-09
US11667688B2 (en) 2023-06-06
AR105485A1 (es) 2017-10-11
US10696725B2 (en) 2020-06-30
EP4523705A3 (fr) 2025-06-11
KR102005456B1 (ko) 2019-07-30
IL291291A (en) 2022-05-01
PT3322437T (pt) 2024-03-20
CL2023001911A1 (es) 2023-11-17
KR102395855B1 (ko) 2022-05-10
JP2021102618A (ja) 2021-07-15
EP4324519A2 (fr) 2024-02-21
MA41887B1 (fr) 2020-05-29
FI3322437T3 (fi) 2024-02-20
ES2973017T3 (es) 2024-06-18
JP2018526333A (ja) 2018-09-13
PE20240215A1 (es) 2024-02-16
US11261227B2 (en) 2022-03-01
KR20170003466A (ko) 2017-01-09
CO2018000303A2 (es) 2018-07-10
JP7626393B2 (ja) 2025-02-07
CL2023000198A1 (es) 2023-06-30
NZ739250A (en) 2024-02-23
CA2991107C (fr) 2025-09-09
JP2023062043A (ja) 2023-05-02
TN2017000555A1 (en) 2019-04-12
BR112017028517A2 (pt) 2018-08-28
PH12017502393A1 (en) 2018-06-25
WO2017003191A1 (fr) 2017-01-05
CR20180034A (es) 2018-04-16
EP3322437A1 (fr) 2018-05-23
EP4324519A3 (fr) 2024-07-24
CA3273336A1 (en) 2025-10-30
HK1248129A1 (en) 2018-10-12
CL2017003402A1 (es) 2018-04-20
AU2023201118B2 (en) 2026-02-19
EA201890058A1 (ru) 2018-07-31
EP3322437B1 (fr) 2024-01-17
CA2991107A1 (fr) 2017-01-05
AU2016287209A1 (en) 2018-02-15
JP6882210B2 (ja) 2021-06-02
EP4523705A2 (fr) 2025-03-19
KR20190092343A (ko) 2019-08-07
US20200223897A1 (en) 2020-07-16
MA49545B1 (fr) 2022-03-31
AU2023201118A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
MA41887A1 (fr) Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
BR112018001955A2 (pt) anticorpos monoclonais contra bcma
LT3577110T (lt) 8-oksetan-3-il-3,8-diazabiciklo[3.2.1]oktan-3-ilo pakeistieji junginiai, kaip živ inhibitoriai
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
CR20160419A (es) Nuevos compuestos biciclicos
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
EA201992177A1 (ru) Композиции на основе нирапариба
EP3497210A4 (fr) Nouvelles compositions de glucose oxydase
EP3660019C0 (fr) 7h-pyrazolo[3,4-d]triazine-2-oxides en tant qu'explosifs
MA45857A (fr) Composés et compositions, et utilisations associées
CL2019003599S1 (es) Extintor.
EP3856191A4 (fr) Nouvelles utilisations
EP3620471A4 (fr) Conjugué anticorps-médicament anti-fibrine insoluble pouvant être clivé par la plasmine
MA45795A (fr) Composés et compositions, et utilisations associées
EA201792492A1 (ru) Aml-антигены и их применение
MA42889B2 (fr) Triple activateur activant le récepteur du glucagon, du glp-1 et du gip
FR3056590B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
FR3056585B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
CL2019002372S1 (es) Portalón.
IT201700080501A1 (it) Riduttore.
UA107468U (uk) 25,27-ди-(5-тіо-октилокси)калікс[4]арен-краун-6
TN2014000522A1 (fr) لوح مدرسي بوجهين
FR3056586B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane
FR3056587B1 (fr) Composition comprenant du 1-chloro-2,2-difluoroethane